Compare Eli Lilly And Co (LLY) vs MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs MONDELEZ INTERNATIONAL INC Common Stock — how do they compare? Eli Lilly And Co trades at $1,221.01 (market cap $1.08T), while MONDELEZ INTERNATIONAL INC Common Stock trades at $62.21 (market cap $78.85B). The key difference: Eli Lilly And Co is far larger — about 13.7× MONDELEZ INTERNATIONAL INC Common Stock's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays the higher dividend (3.24%). Which is the better fit depends on your goals.
| LLY | MDLZ | |
|---|---|---|
Market Cap | $1.08T | $78.85B |
Sector | Health | Consumer Staples |
52-Week High | $1.24K | $64.99 |
52-Week Low | $639.43 | $51.51 |
Enterprise Value | $1.13T | $99.19B |
Dividend Yield | 0.57% | 3.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,223.97, down 0.62% on the day, maintaining strong bullish momentum with consecutive earnings beats and robust revenue growth. The stock shows technical strength above key support levels at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 102.44% ROE. Recent quarterly results exceeded expectations, with Q2 2026 revenue surging 48% to $23 billion driven by Mounjaro and Zepbound demand.
Outlook remains positive with analyst consensus targeting $1,380 and 73% buy ratings, though elevated valuations (P/E 40.8) and regulatory risks around weight-loss drug competition present headwinds. The company's pipeline advancement with retatrutide filing expected in 2027 provides medium-term growth catalysts, but investors should monitor execution risks in the competitive obesity drug market.
MDLZ trades at $61.99, up 0.75% today, with a bullish technical signal from moving averages and support at $61. The company reported Q2 2026 EPS of $0.73, beating estimates, and raised its organic sales outlook. Revenue grew to $38.54B in 2025, though net income margin declined to 6.36%. Analyst consensus is strongly bullish with a $70.50 price target.
Outlook is positive due to earnings beats and emerging market growth, but risks include margin pressure and high P/E of 37.75. Institutional activity is mixed, with some firms increasing stakes while others reduced holdings. The stock offers upside to target but faces execution risks in a competitive consumer staples sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →
